CROWN and BRIGHTSTAR Studies: Latest Data Insights
October 25th 2024Panelists discuss the key findings from the latest data from the CROWN and BRIGHTSTAR studies, emphasizing efficacy end points and comparing the effectiveness of these regimens with that of others in the treatment landscape for ALK-positive NSCLC.
Read More
Molecular Testing and First-Line Treatment Selection in ALK-Positive NSCLC
October 25th 2024Panelists discuss the importance of molecular testing in NSCLC, particularly for ALK rearrangements, and explore how recent advancements and emerging technologies are shaping first-line treatment selection for ALK-positive patients.
Read More
Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC
August 23rd 2016Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer.
Read More